AOD-9604 research guide for Aya. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Aya looking to source AOD-9604, the key fact to understand is that this compound is distributed via specialist online vendors. The practical takeaway for Aya researchers: sourcing AOD-9604 hinges on vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. The sections below cover what Aya researchers need to know about finding, evaluating, and storing AOD-9604 for research purposes.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Aya comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
The first step for any Aya researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — commercial rankings reflect SEO budgets rather than product quality. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger serious immune reactions even at minute levels. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. Keep lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Aya
COA-verified · International tracking · Research grade
All use of AOD-9604 in Aya or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Lyophilised AOD-9604 should be placed in the freezer at −20°C straight away; do not freeze and thaw reconstituted AOD-9604 multiple times by preparing small aliquots before storage. Endotoxin testing in the AOD-9604 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at minute levels, and no pricing advantage justifies skipping this verification. Researchers using AOD-9604 alongside other research compounds should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
